Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

KRC 01

Next Previous
Drug Profile

KRC 01

Alternative Names: H2O2/sodium hyaluronate - KORTUC; KRC-01

Latest Information Update: 12 Jun 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kortuc; Okayama University
  • Developer Kortuc
  • Class Antibacterials; Antineoplastics; Antiseptics; Disinfectants; Peroxides; Radiosensitisers
  • Mechanism of Action Catalase inhibitors; Peroxidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Breast cancer
  • Phase I/II Cervical cancer; Solid tumours

Most Recent Events

  • 09 Jun 2026 Kortuc plans a clinical trials for cervical cancer and rectal cancer in United Kingdom, France, India, Thailand and USA
  • 02 Jun 2026 Gustave Roussy plans the phase II K-BOOST Study trial for Rectal Cancer (Late-stage disease, Adjunctive treatment) in France, in July 2026 (Intratumoural, Injection) (CSET-number2025/4237) (CTIS2025-524378-40-00) (NCT07622017)
  • 02 Jun 2026 KORTUC plans a phase II trial for Rectal cancer (Late-stage disease) in France (Intratumoural, Injection) in July 2026 (NCT07622017)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top